World Equity Group’s Biogen BIIB Stock Holding History

World Equity Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,010	Closed	-$72.7K	–	337
2023 Q1	$72.7K	Buy	+21,010	New	+$5.81M	0.01%	503

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

World Equity Group's BIIB Position: Q2 2023 in Review

World Equity Group sold out of Biogen (BIIB) in Q2 2023, closing a stake of 21,010 shares — an estimated $72.7K sold.

World Equity Group first reported a position in BIIB in Q1 2023 and held it in 1 quarter. The position peaked at $72.7K in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

World Equity Group reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
World Equity Group sold 21,010 Biogen shares in Q2 2023, an estimated $72.7K.
World Equity Group first reported a position in Biogen in Q1 2023 and held it in 1 quarter.
World Equity Group's Biogen position peaked at $72.7K in Q1 2023.
1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on World Equity Group's 13F filing for Q2 2023, filed 26 Aug 2024.